We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Rocket Pharmaceuticals Inc
18 own
11 watching
Current Price
$22.8
$-0.68
(-2.9%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,577.42M
52-Week High
32.52500
52-Week Low
14.89000
Average Volume
0.96M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,577.42M52-Week High32.5250052-Week Low14.89000Average Volume0.96MDividend Yield--P/E Ratio--What does the Rocket Pharmaceuticals Inc do?
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The product pipeline includes Trabodenoson, a monotherapy dosed in an eye drop that is in Phase III clinical trials; Trabodenoson-Latanoprost Fixed-Dose Combination, which has completed Phase II study for use in patients with higher intraocular pressures; and Trabodenoson for optic neuropathy and degenerative retinal diseases. The company was founded in 1999 and is headquartered in Lexington, Massachusetts.
Read More
How much money does Rocket Pharmaceuticals Inc make?
News & Events about Rocket Pharmaceuticals Inc.
Zolmax
12 months ago
StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT Get Rating) to a sell rating in a report issued on Wednesday. Several other equities research analysts have also recently commented on RCKT. William Blair reaffirmed an outperform rating on shares of Rocket Pharmaceuticals in a ...
Benzinga
1 year ago
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.
read more...
Zolmax
1 year ago
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Rating) has earned a consensus rating of Moderate Buy from the fourteen analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and twelve have issued a buy recommendation on the ...
Ticker Report
1 year ago
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Rating) have received a consensus rating of Moderate Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation ...
Business Wire
1 year ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and...
Frequently Asked Questions
Frequently Asked Questions
What is Rocket Pharmaceuticals Inc share price today?
Can Indians buy Rocket Pharmaceuticals Inc shares?
How can I buy Rocket Pharmaceuticals Inc shares from India?
Can Fractional shares of Rocket Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Rocket Pharmaceuticals Inc stocks?
What is today’s traded volume of Rocket Pharmaceuticals Inc?
What is today’s market capitalisation of Rocket Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Rocket Pharmaceuticals Inc?
What percentage is Rocket Pharmaceuticals Inc down from its 52-Week High?
What percentage is Rocket Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$22.8
$-0.68
(-2.9%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.